Impact of Reduction of Dust Mite Allergenic Load on Step Down of Inhaled Corticosteroids in Stable Asthma

Asthma Clinical Trial

Official title:

Impact of Reduction of Dust Mite Allergenic Load on Step Down of Inhaled Corticosteroids in Stable Asthma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02773628
• Other study ID #: AK/15-12-127/4581
• Status: Terminated
• Phase: N/A
• Start date: May 2016
• Est. completion date: August 2018

Study information

• Verified date: February 2019
• Source: Centre Hospitalier Universitaire Saint Pierre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Eviction methods for dust mite allergy have been evaluated in asthma control in a recent Cochrane meta-analysis. None have shown efficacy on asthma control and there are not recommended. The purpose is to evaluate the efficacy of a new commercialized system (Acar'Up) to decrease dust mite load and to assess its impact on the possibility to perform inhaled corticosteroids step down in stable asthmatics.

Description:

Eviction methods for dust mite allergy have been evaluated in asthma control in a recent Cochrane meta-analysis. None have shown efficacy on asthma control and there are not recommended. The purpose is to evaluate the efficacy of a new commercialized system, Acar'Up (a spray pulverized on a technical textile that traps the dust mite) to decrease dust mite load and to assess its impact on the possibility to perform inhaled corticosteroids step down in stable asthmatics.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: August 2018
• Est. primary completion date: August 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 100 Years

Eligibility

Inclusion Criteria:

• confirmed asthma diagnosis

• controlled asthma for more than 3 months

• treatment with inhaled corticosteroids

• dust mite allergy proved by skin tests ou specific immunoglobulin E

Exclusion Criteria:

• chronic obstructive pulmonary disease, bronchiectasis, Fibrosis, tuberculosis

• asthma-chronic obstructive pulmonary disease overlap syndrome

• ongoing desensitization for dust mite

• pregnancy

• previous use of Acar'up

Related Conditions & MeSH terms

• Asthma

Intervention

Device:
• Acar'up system

• Acar'up placebo system

Locations

Country	Name	City	State
Belgium	CHu Saint Pierre	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Saint Pierre

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	assessment of successful stepdown of inhaled corticosteroid using clinical evaluation	assessment of the successful step down of inhaled corticosteroid using clinical evaluation	4 months
Primary	assessment of successful stepdown of inhaled corticosteroid using asthma scale: asthma control questionnaire (ACQ)	assessment of the successful step down of inhaled corticosteroid using asthma scale: asthma control questionnaire (ACQ)	4 months
Primary	assessment of successful stepdown of inhaled corticosteroid using asthma quality of life questionnaire (AQLQ)	assessment of the successful step down of inhaled corticosteroid using asthma quality of life questionnaire (AQLQ)	4 months
Secondary	assessment of asthma control by the asthma control questionnaire questionnaire	by the asthma control questionnaire	4 months
Secondary	assessment of asthma quality of life by the asthma quality of life questionnaire	by the asthma quality of life questionnaire	4 months
Secondary	assessment of rhinitis control by the rhinitis quality of life questionnaire	by the rhinitis quality of life questionnaire	4 months